Earnings due: Sanofi India (SANOFI.NS) NSE pre-market 25 Feb 2026: guidance is key
SANOFI.NS stock is in focus pre-market on 25 Feb 2026 as Sanofi India Limited (SANOFI.NS) reports Q4 results today. The company trades on the NSE in India at INR 4080.70 and carries a price-to-earnings of 26.35 based on the latest quote. Investors will watch revenue, margin trends and management guidance closely, since the market often re-prices healthcare names on forward guidance. Sanofi India’s EPS is 154.89 and the company pays a high dividend per share of 192.00 INR, both key inputs for near-term moves.
SANOFI.NS stock: Earnings timing and what to expect
Sanofi India Limited (SANOFI.NS) releases Q4 results on 25 Feb 2026 with an earnings announcement scheduled for the day. Expect the company to report quarter revenue, net profit and commentary on domestic demand and export volumes. Management guidance on pricing, margin and distributor inventory will be the immediate catalyst for intra-day moves in the pre-market and opening session.
SANOFI.NS stock: Price and valuation snapshot
The stock trades at INR 4080.70 on the NSE with a one-day change of -0.41% and volume of 12,254 shares. Day low is 4063.00 and day high is 4123.90, with a 52-week range of 3976.00 to 6717.00. Key ratios: PE 26.35, EPS 154.89, price average 50-day 4080.85 and 200-day 4999.09, showing the stock trades below its long-term moving average.
SANOFI.NS stock: Meyka AI grade and model forecast
Meyka AI rates SANOFI.NS with a score out of 100 — 71.39 / B+ (BUY). This grade factors S&P 500 and sector comparisons, financial growth, key metrics and analyst consensus. Meyka AI’s forecast model projects a yearly price of INR 5439.19, a monthly target of INR 4182.51, and a quarterly target of INR 4143.21. Compared with the current price of INR 4080.70, the yearly projection implies an upside of 33.31%, the monthly target implies 2.50%, and the quarterly target implies 1.53%. Forecasts are model-based projections and not guarantees.
SANOFI.NS stock: Technical and sector context
Technicals show neutral momentum with RSI 52.74 and MACD histogram positive at 11.06, suggesting short-term stabilization. Bollinger middle band sits at 4036.36 and ATR is 66.43, so expect typical INR 60–70 price swings intraday. The Healthcare sector (India) has underperformed YTD, and peers trade at a higher average PE, so SANOFI.NS stock’s relative performance will track sector flows and defensive demand.
SANOFI.NS stock: Risks and near-term catalysts
Near-term catalysts include Q4 revenue, margins and management guidance, plus distributor inventory trends. Key risks are a high price-to-book of 12.02, concentrated brand exposure and demographic demand shifts. The stock pays a dividend yield near 4.71%, which supports income investors but increases sensitivity to payout changes. For recent healthcare sector headlines that can shift sentiment see the earnings and biotech coverage source and broader earnings transcripts source.
SANOFI.NS stock: Practical scenarios and price targets
Scenario-based price map: conservative downside target INR 3900.00 (−4.40%), base case INR 4500.00 (+10.35%), and bullish yearly model INR 5439.19 (+33.31%). Traders may watch guidance and set a stop near the 50-day average INR 4080.85 if Q4 misses. Long-term investors should compare SANOFI.NS stock’s dividend yield and ROE against sector peers before adjusting allocations. See the Meyka stock page for live data and alerts at Meyka SANOFI.NS page.
Final Thoughts
Sanofi India (SANOFI.NS) arrives at the NSE pre-market session on 25 Feb 2026 with Q4 results that can move the stock. At INR 4080.70 the market prices a mid-teens valuation and a dividend yield near 4.71%, leaving room for a re-rate if management confirms margin expansion or stronger export growth. Meyka AI’s forecast model projects a yearly level of INR 5439.19, implying a 33.31% upside from the current price, while short-term monthly and quarterly targets are modest at INR 4182.51 and INR 4143.21. Our Meyka grade of 71.39 (B+, BUY) reflects solid cash flow metrics and low leverage but flags valuation and margin execution as watchpoints. Earnings-day guidance and any change to the dividend policy will be primary drivers; use tight risk controls if trading the release. Forecasts are model-based projections and not guarantees, and investors should combine this analysis with their own research and risk profile. Meyka AI provides this as an AI-powered market analysis platform illustration, not investment advice.
FAQs
When will SANOFI.NS stock report earnings and what matters most?
SANOFI.NS stock reports Q4 results on 25 Feb 2026. Investors should focus on revenue growth, operating margin, export volumes and management guidance for FY27, as these items drive immediate share reaction.
How expensive is SANOFI.NS stock versus peers?
SANOFI.NS stock trades at PE 26.35, above some domestic peers but below its 52-week high. Price-to-book at 12.02 signals premium valuation relative to balance sheet metrics.
What does Meyka AI forecast for SANOFI.NS stock?
Meyka AI’s forecast model projects a yearly price of INR 5439.19, implying a 33.31% upside from the current INR 4080.70. These projections are model-based and not guarantees.
What are the main risks for SANOFI.NS stock after earnings?
Main risks include weaker-than-expected margins, distributor destocking, regulatory changes and any cut to the dividend. High valuation metrics can amplify downside on a profit miss.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.